The latest installment in BioPharma Dive’s data visualization series features a look at the emerging popularity of RNAi ...
Early CDMO engagement can be valuable, particularly when it helps development teams understand technical requirements, ...
U.S. regulators have accepted a new submission for Vyglxia, offering the chance at a turnaround for another rare disease ...
Shortly after winning a clearance in the skin disease dermatomyositis, brepocitinib posted results suggesting it might also ...
Hibsago is viewed as a potential “functional cure” for chronic infections and an important part of the British drugmaker’s ...
The acquisition gives the German company a promising blood disorder medicine that passed a Phase 2 test and could threaten a ...
Roche is paying Hansoh $400 million up front in a broad deal involving several ADCs. Elsewhere, another top investor formed a ...
Months after the FDA rejected its treatment for a rare light-sensitivity disease, the biotech claimed success in a Phase 3 ...
The launch prices of two-thirds of the new prescription drugs reviewed by the watchdog group ICER between 2022 and 2025 far exceeded the organization’s threshold of cost-effectiveness, according to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results